p.106 抽出テキスト

Circulation. 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 September 25, 2018 e377 CLINICAL STATEMENTS AND GUIDELINES

S7.9.1.3-12.	 Antzelevitch C, Yan GX, Ackerman MJ, et al. J-wave syndromes expert consensus conference report: emerging concepts and gaps in knowledge. Europace. 2017;19:665–94. S7.9.1.3-13.	 Delise P, Allocca G, Marras E, et al. Risk stratification in individuals with the Brugada type 1 ECG pattern without previous cardiac arrest: usefulness of a combined clinical and electrophysiologic approach. Eur Heart J. 2011;32:169–76. S7.9.1.3-14.	 Somani R, Krahn AD, Healey JS, et al. Procainamide infusion in the evaluation of unexplained cardiac arrest: from the Cardiac Arrest Survivors with Preserved Ejection Fraction Registry (CASPER). Heart Rhythm. 2014;11:1047–54. S7.9.1.3-15.	 Kusumoto FM, Bailey KR, Chaouki AS, et al. Systematic review for the 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018;138:e392–e414. S7.9.1.3-16.	 Sieira J, Ciconte G, Conte G, et al. Asymptomatic Brugada syndrome: clinical characterization and long-term prognosis. Circ Arrhythm Electrophysiol. 2015;8:1144–50. S7.9.1.3-17.	 Sieira J, Conte G, Ciconte G, et al. Prognostic value of programmed electrical stimulation in Brugada syndrome: 20 years experience. Circ Arrhythm Electrophysiol. 2015;8: 777–84. S7.9.1.3-18.	 Crotti L, Marcou CA, Tester DJ, et al. Spectrum and prevalence of mutations involving BrS1- through BrS12-susceptibility genes in a cohort of unrelated patients referred for Brugada syndrome genetic testing: implications for genetic testing. J Am Coll Cardiol. 2012;60:1410–8. S7.9.1.3-19.	 Probst V, Wilde AA, Barc J, et al. SCN5A mutations and the role of genetic background in the pathophysiology of Brugada syndrome. Circ Cardiovasc Genet. 2009;2:552–7. S7.9.1.3-20.	 Risgaard B, Jabbari R, Refsgaard L, et al. High prevalence of genetic variants previously associated with Brugada syndrome in new exome data. Clinical Genetics. 2013;84:489–95. S7.9.1.3-21.	 Brugada drugs. Available at: http://www.brugadadrugs.org. Accessed October 6, 2016. S7.9.1.3-22.	 Postema PG, Wolpert C, Amin AS, et al. Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). Heart Rhythm. 2009;6:1335–41. S7.9.1.3-23.	 Andorin A, Behr ER, Denjoy I, et al. Impact of clinical and genetic findings on the management of young patients with Brugada syndrome. Heart Rhythm. 2016;13:1274–82. S7.9.1.3-24.	 Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Heart Rhythm. 2013;10:1932–63. S7.9.1.3-25.	 McNamara DA, Goldberger JJ, Berendsen MA, et al. Implantable defibrillators versus medical therapy for cardiac channelopathies. Cochrane Database Syst Rev. 2015;CD011168. S7.9.1.3-26.	 Nademanee K, Veerakul G, Mower M, et al. Defibrillator versus beta-blockers for unexplained death in Thailand (DEBUT): a randomized clinical trial. Circulation. 2003;107:2221–6. S7.9.1.3-27.	 Rodriguez-Manero M, Sacher F, de AC, et al. Monomorphic ventricular tachycardia in patients with Brugada syndrome: a multicenter retrospective study. Heart Rhythm. 2016;13: 669–82. S7.9.1.3-28.	 Brugada R, Brugada J, Antzelevitch C, et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation. 2000;101:510–5. S7.9.1.3-29.	 Shimeno K, Takagi M, Maeda K, et al. Usefulness of multichannel Holter ECG recording in the third intercostal space for detecting type 1 Brugada ECG: comparison with repeated 12-lead ECGs. J Cardiovasc Electrophysiol. 2009;20:1026–31. S7.9.1.3-30.	 Conte G, Sieira J, Ciconte G, et al. Implantable cardioverter-defibrillator therapy in Brugada syndrome: a 20-year single-center experience. J Am Coll Cardiol. 2015;65:879–88. S7.9.1.3-31.	 Kapplinger JD, Tester DJ, Alders M, et al. An international com-

pendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm. 2010;7:33–46. S7.9.1.3-32.	 Adler A, Rosso R, Chorin E, et al. Risk stratification in Brugada syn-

drome: clinical characteristics, electrocardiographic parameters, and auxiliary testing. Heart Rhythm. 2016;13:299–310. S7.9.1.3-33.	 Priori SG, Napolitano C, Gasparini M, et al. Natural history of

Brugada syndrome: insights for risk stratification and management. Circulation. 2002;105:1342–7.

7.9.1.4 Early Repolarization “J-wave” Syndrome

S7.9.1.4-1.	Rosso R, Kogan E, Belhassen B, et al. J-point elevation in survivors of primary ventricular fibrillation and matched control subjects: incidence and clinical significance. J Am Coll Cardiol. 2008;52:1231–8. S7.9.1.4-2.	Adhikarla C, Boga M, Wood AD, et al. Natural history of the electrocardiographic pattern of early repolarization in ambulatory patients. Am J Cardiol. 2011;108:1831–5. S7.9.1.4-3.	Haissaguerre M, Sacher F, Nogami A, et al. Characteristics of recurrent ventricular fibrillation associated with inferolateral early repolarization role of drug therapy. J Am Coll Cardiol. 2009;53:612–9. S7.9.1.4-4.	Siebermair J, Sinner MF, Beckmann BM, et al. Early repolarization pattern is the strongest predictor of arrhythmia recurrence in patients with idiopathic ventricular fibrillation: results from a single centre long-term follow-up over 20 years. Europace. 2016;18:718–25. S7.9.1.4-5.	Sinner MF, Porthan K, Noseworthy PA, et al. A meta-analysis of genome-wide association studies of the electrocardiographic early repolarization pattern. Heart Rhythm. 2012;9: 1627–34. S7.9.1.4-6.	Tikkanen JT, Anttonen O, Junttila MJ, et al. Long-term outcome associated with early repolarization on electrocardiography. N Engl J Med. 2009;361:2529–37. S7.9.1.4-7.	Tikkanen JT, Wichmann V, Junttila MJ, et al. Association of early repolarization and sudden cardiac death during an acute coronary event. Circ Arrhythm Electrophysiol. 2012;5:714–8. S7.9.1.4-8.	Junttila MJ, Tikkanen JT, Kentta T, et al. Early repolarization as a predictor of arrhythmic and nonarrhythmic cardiac events in middle-aged subjects. Heart Rhythm. 2014;11:1701–6. S7.9.1.4-9.	Cheng YJ, Lin XX, Ji CC, et al. Role of early repolarization pat-

tern in increasing risk of death. J Am Heart Assoc. 2016;5: e003375.

7.9.1.5 Short QT Syndrome

S7.9.1.5-1.	Dhutia H, Malhotra A, Parpia S, et al. The prevalence and significance of a short QT interval in 18 825 low-risk individuals including athletes. Br J Sports Med. 2016;50:124–9. S7.9.1.5-2.	Gollob MH, Redpath CJRoberts JD, The short QT syndrome: proposed diagnostic criteria. J Am Coll Cardiol. 2011;57:802–1. S7.9.1.5-3.	Giustetto C, Schimpf R, Mazzanti A, et al. Long-term followup of patients with short QT syndrome. J Am Coll Cardiol. 2011;58:587–95. S7.9.1.5-4.	Mazzanti A, Kanthan A, Monteforte N, et al. Novel insight into the natural history of short QT syndrome. J Am Coll Cardiol. 2014;63:1300–8. S7.9.1.5-5.	Villafane J, Atallah J, Gollob MH, et al. Long-term follow-up of a pediatric cohort with short QT syndrome. J Am Coll Cardiol. 2013;61:1183–91. S7.9.1.5-6.	Giustetto C, Di MF, Wolpert C, et al. Short QT syndrome: clinical findings and diagnostic-therapeutic implications. Eur Heart J. 2006;27:2440–7. S7.9.1.5-7.	Bun SS, Maury P, Giustetto C, et al. Electrical storm in short-QT syndrome successfully treated with isoproterenol. J Cardiovasc Electrophysiol. 2012;23:1028–30. S7.9.1.5-8.	Guerrier K, Kwiatkowski D, Czosek RJ, et al. Short QT interval prevalence and clinical outcomes in a pediatric population. Circ Arrhythm Electrophysiol. 2015;8:1460–4. S7.9.1.5-9.	Iribarren C, Round AD, Peng JA, et al. Short QT in a cohort of 1.7 million persons: prevalence, correlates, and prognosis. Ann Noninvasive Electrocardiol. 2014;19:490–500. S7.9.1.5-10.	 Gollob MH, Blier L, Brugada R, et al. Recommendations for the

use of genetic testing in the clinical evaluation of inherited cardiac arrhythmias associated with sudden cardiac death: Canadian Cardiovascular Society/Canadian Heart Rhythm Society joint position paper. Can J Cardiol. 2011;27:232–458.

Downloaded from http://ahajournals.org by on October 7, 2026